KT-253

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients With High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
70 patients (estimated)
Sponsors
Kymera Therapeutics, Inc.
Tags
MDM2 Inhibitor
Trial Type
Treatment
Last Update
5 days ago
SparkCures ID
1828
NCT Identifier
NCT05775406

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.